Anbio Biotechnology (NNNN) Operating cash flow 2022–2025
Anbio Biotechnology (NNNN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$6.7MFY2025 · since FY2022: $4.4M → -$6.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$6.7M | -423.9% |
| FY2024 | $2.1M | +131.6% |
| FY2023 | $898,367 | -79.8% |
| FY2022 | $4.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Net marginNNNN Gross profitNNNN Gross marginNNNN Operating incomeNNNN Operating marginNNNN Free cash flowNNNN Capital expendituresNNNN Return on equityNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Total liabilitiesNNNN Shareholders’ equityNNNN overview →